Australia's largest biopharmaceutical company has posted a massive slump in interim profit, pushing its shares to an eight-year low after the sudden retirement of its chief executive.
CSL's first-half net profit fell 81 per cent to $US401 million ($A567 million), after government policy changes, one-off restructuring costs and impairments severely impacted its bottom line.
